Health
Loma Linda University Health announces study of combination monoclonal antibody treatment for early COVID-19 – Loma Linda University Health
ACTIV-2 is studying multiple early COVID-19 treatments
Loma Linda University Health today announced the phase 2 study of the combination of the two monoclonal antibodies BRII-196 and BRII-198 for the treatment of non-hospitalized individuals with early COVID-19.Loma Linda University Health today announced the phase 2 study of the combination of the two monoclonal antibodies BRII-196 and BRII-198 for the treatment of non-hospitalized individuals with early COVID-19. This study is part of the ACTIV-2 Outpatient Monoclonal Antibodies and Other Therapies…
-
Noosa News21 hours agoMan dies after stabbing in inner-city unit
-
General22 hours agoMiners injured at GM3’s Appin Mine after being buried by coal
-
General16 hours agoDonald Trump and the ghost of Al Capone • Inside Story
-
General9 hours agoFrench far-right supporters rally against Le Pen conviction in Paris